Vor Biopharma (VOR) Share-based Compensation (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Share-based Compensation data on file, last reported at $8.9 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 358.87% year-over-year to $8.9 million in Q1 2026; TTM through Mar 2026 was $34.6 million, a 297.47% increase from a year earlier, with the FY2025 full-year figure at $113.4 million, up 1051.62% from the prior year.
• Share-based Compensation for Q1 2026 stood at $8.9 million, down from $15.8 million in the prior quarter.
• Over the last five years, Share-based Compensation for VOR reached as high as $16.6 million in Q4 2022 and fell as low as -$10.3 million in Q4 2023.
• Historically, Share-based Compensation has averaged $3.8 million across 5 years, with a median of $2.3 million in 2024.
• Across the five-year window, Share-based Compensation jumped 1276.56% in 2022 and plunged 162.08% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at $16.6 million in 2022, then plunged by 162.08% to -$10.3 million in 2023, then soared by 116.62% to $1.7 million in 2024, then surged by 826.45% to $15.8 million in 2025, then sank by 43.98% to $8.9 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $8.9 million in Q1 2026, $15.8 million in Q4 2025, and $8.0 million in Q3 2025.